The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Late-stage drug development efforts have many moving parts as projects push toward commercialization. During this critical time, companies often take a good long look at their vendors and evaluate their options for scale up to commercial launch.
Is your CDMO an asset or a hindrance in this process? How can you recognize whether your partners really contribute everything they can to your end goal of commercialization?
This article focuses on 10 red flags that could signal it is time to start looking elsewhere for a CDMO that can efficiently bring your project to commercialization while steering clear of potential roadblocks along the way.